BCL6 and bladder transitional cell carcinoma: Additionally, recent reports have indicated that BCL6 suppresses FOXO3 activity through the activation of the PI3K‒AKT signaling pathway in urinary bladder urothelial carcinoma (Wu et al., 2020).